Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig

Circulation. 2007 Jan 23;115(3):326-32. doi: 10.1161/CIRCULATIONAHA.106.647230. Epub 2007 Jan 8.

Abstract

Background: Cyclooxygenase (COX)-2 expression in the heart increases after myocardial infarction (MI). In murine models of MI, COX-2 inhibition preserves left ventricular dimensions and function. We studied the effect of selective COX-2 inhibition on left ventricular remodeling and function after MI in a pig model.

Methods and results: Twenty-two pigs were assigned to COX-2 inhibition with a COX-2 inhibitor (COX-2i; celecoxib 400 mg twice daily; n=14) or a control group (n=8). MI was induced by left circumflex coronary artery ligation, and the animals were euthanized 6 weeks later. Cardiac dimensions and function were assessed with echocardiography and conductance catheters. Infarct size and collagen density were analyzed with triphenyltetrazolium chloride staining and picrosirius red staining, respectively. COX-2 inhibition increased mortality compared with controls (50% versus 0%, P=0.022), whereas infarct size was similar (13.1+/-0.7% versus 14.1+/-0.1%, P=0.536). The decrease in thickness of the infarcted myocardial wall was more pronounced in the COX-2i group (60.6+/-9.6% versus 36.2+/-5.7%, P=0.001). End-diastolic volume was higher in the COX-2i group (133.9+/-33.5 versus 91.1+/-24.0 mL; P=0.021), as was the end-systolic volume at 100 mm Hg (81.7+/-27.8 versus 56.3+/-21.1 mL; P=0.037), which indicates that systolic function was more severely impaired. Infarct collagen density was lower after COX-2i treatment (25.3+/-3.9 versus 56.1+/-23.8 gray value/mm2; P=0.005).

Conclusions: In pigs, COX-2 inhibition after MI is associated with increased mortality, enhanced left ventricular remodeling, and impaired systolic function, probably due to decreased infarct collagen fiber density.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Cardiovascular Diseases / enzymology
  • Cardiovascular Diseases / pathology
  • Celecoxib
  • Collagen / metabolism
  • Cyclooxygenase 2 / drug effects
  • Cyclooxygenase 2 / metabolism*
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / pharmacology
  • Disease Models, Animal
  • Female
  • Myocardial Infarction / enzymology*
  • Myocardial Infarction / mortality
  • Pyrazoles / adverse effects*
  • Pyrazoles / pharmacology
  • Risk Factors
  • Sulfonamides / adverse effects*
  • Sulfonamides / pharmacology
  • Swine
  • Systole / drug effects
  • Systole / physiology*
  • Ventricular Remodeling / drug effects
  • Ventricular Remodeling / physiology*

Substances

  • Cyclooxygenase Inhibitors
  • Pyrazoles
  • Sulfonamides
  • Collagen
  • Cyclooxygenase 2
  • Celecoxib